Abstract: Alkyl-piperazine-phenyl 4 (3H)-quinazolinones compounds of general formula (I) below are provided that are pharmacologically active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, including loss of sexual desire, inhibition of sexual desire and absence of sexual desire, among other disorders associated with these receptors.
Type:
Grant
Filed:
September 23, 2015
Date of Patent:
May 3, 2016
Assignees:
ACHE LABORATORIOS FARMACEUTICOS S.A., ACHE INTERNATIONAL (BVI) LTD.
Inventors:
Valter Freire Torres Russo, Elisa Mannochio De Souza Russo
Abstract: The present invention relates to a method for treating comorbid anxiety disorders and depression disorders, as well as for preventing depression disorders in individuals affected by anxiety disorders, by administering a therapeutically effective amount of the compound of general formula (I): wherein R1 is —OCH3 or —CN or suitable pharmaceutical salts, hydrates or anhydrates thereof.
Type:
Grant
Filed:
April 14, 2014
Date of Patent:
November 10, 2015
Assignees:
ACHE LABORATORIOS FARMACEUTICOS S.A., ACHE INTERNATIONAL (BVI) LTD.
Inventors:
Valter Freire Torres Russo, Elisa Mannochio De Souza Russo
Abstract: This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologicaly active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.
Type:
Grant
Filed:
March 27, 2014
Date of Patent:
October 27, 2015
Assignees:
ACHE LABORATORIOS FARMACEUTICOS S.A., ACHE INTERNATIONAL (BVI) LTD.
Inventors:
Valter Freire Torres Russo, Elisa Mannochio De Souza Russo
Abstract: The present invention relates to a method for treating comorbid anxiety disorders and depression disorders, as well as for preventing depression disorders in individuals affected by anxiety disorders, by administering a therapeutically effective amount of the compound of general formula (I): wherein R1 is —OCH3 or —CN or suitable pharmaceutical salts, hydrates or anhydrates thereof.
Type:
Application
Filed:
April 14, 2014
Publication date:
January 15, 2015
Applicants:
ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A., ACHÉ INTERNATIONAL (BVI) LTD.
Inventors:
Valter FREIRE TORRES RUSSO, Elisa MANNOCHIO DE SOUZA RUSSO
Abstract: This invention is related to the alkyl-piperazine-phenyl 4(3H)-quinazolinones compounds of general formula (I) below: which are pharmacologicaly active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.
Abstract: This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologicaly active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.
Type:
Application
Filed:
March 27, 2014
Publication date:
October 9, 2014
Applicants:
ACHÉ INTERNATIONAL (BVI) LTD., ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. ATC Trustees, Abbot Building, 2nd Floor, Road Town
Inventors:
Valter FREIRE TORRES RUSSO, Elisa MANNOCHIO DE SOUZA RUSSO
Abstract: This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologically active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.
Type:
Grant
Filed:
September 22, 2011
Date of Patent:
May 27, 2014
Assignees:
Aché Laboratórios Farmacêuticos S.A., Aché International (BVI) Ltd.
Inventors:
Valter Freire Torres Russo, Elisa Mannochio De Souza Russo
Abstract: This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologically active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.
Type:
Application
Filed:
September 22, 2011
Publication date:
July 18, 2013
Applicants:
ACHÉ INTERNATIONAL (BVI) LTD., ACHÉ LABORATORIOS FARMACÊUTICOS S.A.
Inventors:
Valter Freire Torres Russo, Elisa Mannochio De Souza Russo